Friday, December 08, 2006

 

MDB Capital Initiates Coverage of MVIS with Buy

Click here to download research report.

Just hit Briefing.com (Who's your Daddy?)

10:46 MVIS Microvision initiated with a Buy at MDB Capital- tgt $6 (2.73 +0.00)

MDB initiates MVIS with a Buy and a $6 tgt saying significant price appreciation is possible in these shares if the co can demonstrate shortly an operable IPM design in the new micro-form factor.

Comments:
I’ve joined you on MVIS, and added to the position this morning based on your accurate ongoing critique, track record of your archived postings, and your apparent enthusiasm. However, today’s research paper/coverage, from the underwriter of the secondary, doesn’t blow wind up my skirt.
 
Dan-

You wear a skirt?
 
Dan must be a Scotsman. Underwriter reports aren't the trash the used to be. The jokers slapping the targets on are not part of, or compensated for, IB work. Take a look at the shitshow targets slapped on APKT and OPTM recently. And recall the VG underwriters initiated well beneath the offering price. now VG is a piece of shit, chaired by a scumbag, I might add. but the other 2 companies rock. Should have seen targets set 30% higher min
 
Great site Broker A, and I'm really enjoying the read. Can you tell me how I can get a copy of the MDB Capital report on MVIS? It's no longer on your link.....Thanks!
 
I will repost it.
 
Too cool, Broker A, and many appreciate your efforts.....and may your lover fill your stockings with exciting gifts for everyday of next year!
 
Post a Comment

Links to this post:

Create a Link



<< Home

This page is powered by Blogger. Isn't yours?

 Subscribe in a reader

DISCLAIMER: This is a personal web site, reflecting the opinions of its author. It is not a production of my employer, and it is unaffiliated with any FINRA broker/dealer. Statements on this site do not represent the views or policies of anyone other than myself. The information on this site is provided for discussion purposes only, and are not investing recommendations. Under no circumstances does this information represent a recommendation to buy or sell securities.